Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's
disease and are at very high risk of developing early-onset dementia, which is now the …
disease and are at very high risk of developing early-onset dementia, which is now the …
Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies
Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
Challenges in the practical implementation of blood biomarkers for Alzheimer's disease
M Schöll, IMW Verberk, M Del Campo… - The Lancet Healthy …, 2024 - thelancet.com
Blood biomarkers have emerged as accessible, cost-effective, and highly promising tools for
advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal …
advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal …
Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls
The recent introduction of new-generation immunoassay methods allows the reliable
quantification of structural brain markers in peripheral matrices. Neurofilament light chain …
quantification of structural brain markers in peripheral matrices. Neurofilament light chain …
Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study
Background The diagnosis of symptomatic Alzheimer's disease is a clinical challenge in
adults with Down syndrome. Blood biomarkers would be of particular clinical importance in …
adults with Down syndrome. Blood biomarkers would be of particular clinical importance in …
Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome
Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) constitute
genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in …
genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in …
Detection of brain tau pathology in Down syndrome using plasma biomarkers
S Janelidze, BT Christian, J Price, C Laymon… - JAMA …, 2022 - jamanetwork.com
Importance Novel plasma biomarkers, especially phosphorylated tau (p-tau), can detect
brain tau aggregates in Alzheimer disease. Objective To determine which plasma biomarker …
brain tau aggregates in Alzheimer disease. Objective To determine which plasma biomarker …
Longitudinal clinical and cognitive changes along the Alzheimer disease continuum in Down syndrome
L Videla, B Benejam, J Pegueroles… - JAMA network …, 2022 - jamanetwork.com
Importance Alzheimer disease (AD) is the main medical problem in adults with Down
syndrome (DS). However, the associations of age, intellectual disability (ID), and clinical …
syndrome (DS). However, the associations of age, intellectual disability (ID), and clinical …
Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist
Blood-based biomarkers offer a major advance in the clinical evaluation of
neurodegenerative diseases. Currently, research studies have reported robust assays of …
neurodegenerative diseases. Currently, research studies have reported robust assays of …
[HTML][HTML] IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by
stunted growth, cognitive impairment, and increased risk of diverse neurological conditions …
stunted growth, cognitive impairment, and increased risk of diverse neurological conditions …